Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

HR 1632, the *Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025*, would allow the FDA to grant "reciprocal marketing approval" for drugs, biological products, and medical devices already approved in specific countries (like those listed in section 802(b)(1) or the UK). This would let manufacturers market these products in the U.S. without going through a full U.S. approval process, provided they meet safety and effectiveness criteria and address unmet medical needs. The FDA must make a decision within 30 days of a request, and Congress could override denials using a joint resolution. This directly affects drug/device manufacturers seeking faster U.S. market access for foreign-approved treatments.